Net loss (GAAP) widened year over year for the six months ended Q2 2025, driven by sharply higher research and administrative expenses. Revenue (GAAP) fell 31.0% year-over-year for the six months ...

Lantern Pharma reported a GAAP net loss per share of ($0.40) in Q2 2025, and marking an improvement from ($0.46) per share (GAAP) in Q2 2024. As expected for a clinical-stage biotech, no product ...